24
Jul
M&A will continue to be a critical tool to unlock value and drive innovation across health industries as dealmakers gear up for a busy second half of 2024.
By Christian K. Moldt, Global Health Industries Deals Leader, Partner, PwC Germany | Dealmakers in pharmaceuticals and life sciences and in healthcare services are eager to get deals done in 2024 as they grow more comfortable navigating an environment of elevated interest rates and regulatory pressure. Competition for truly innovative assets remains...